We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Erbitux

News List

WellmarkerBio receives approval for Phase I clinical trial from the Australian Therapeutic Goods Administration prnasia
March 04, 2021
Wellmarker Bio announced that on February 23, 2021 the company received approval from the Australian Therapeutic Goods Administration (TGA) for a Phase I clinical trial using WM-S1-030, a targeted anti-cancer drug for colorectal cancer and progressive ...
EU nod for new metastatic colorectal cancer combination pharmatimes
June 05, 2020
Pierre Fabre's Braftovi (encorafenib) has been approved in Europe for use alongside Erbitux (cetuximab) to treat of adults with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy.
Merck’s Erbitux backed by NICE for head and neck cancer pharmatimes
September 05, 2017
Merck’s Erbitux is being recommended for routine NHS use to treat recurrent or metastatic squamous cell cancer of the head and neck.
NICE recommends Merck’s erbitux to treat R/M SCCHN in oral cavity pharmaceutical-technology
August 11, 2017
The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Merck’s erbitux (cetuximab), in combination with platinum-based chemotherapy, to treat recurrent and / or metastatic (R/M) squamous cell carcinoma of the he